Assistant Professor, Medicine, University of Pittsburgh School of Medicine
Hematology
Dr. Hussein A. Tawbi, MD
|
|
Give Review
Doctor Hussein A. Tawbi, MD works in the field of Hematology. Hussein Tawbi is also published. He has 34 publications published. The lastest publication: "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.' Dr. Hussein A. Tawbi accepts all Medicare patients.
Publications
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic LipoSarcoma or LeiomyoSarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Rando...
- Immunotherapy in Sarcoma: Future Horizons.
- Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype.
- A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in Medulloblastoma.
- Matching wits with melanoma Brain metastases: from biology to therapeutics.
- Reply to the letter to the editor of Schilling et al."Differential inï¬uence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efï¬cacy in ...
- A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors.
- Selective BRAF inhibitors make inroads in mutated metastatic Melanoma.
- PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines.
- Dasatinib promotes the expansion of a therapeutically superior T-Cell repertoire in response to dendritic Cell vaccination against melanoma.
- Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
- Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
- Melanoma Brain Metastases: an Unmet Challenge in the Era of Active Therapy.
- Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.
- Targeted therapies: BREAKing a path for progress-dabrafenib confirms class effect.
- Role of PARP Inhibitors in Cancer Biology and Therapy.
- Comparative clinical benefits of Systemic adjuvant therapy for paradigm solid tumors.
- A potential role for nilotinib in KIT-mutated Melanoma.
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma.
- Chemotherapy resistance abrogation in metastatic Melanoma.
- Management of metastatic Melanoma.
- Calcitonin in the treatment of transient osteoporosis of the hip.
- Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced Melanoma receiving neoadjuvant ipilimumab.
- LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
- Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk Melanoma?
- Chordoma: the nonsarcoma primary bone tumor.
- Targeted Therapies in Cancer - Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation.
- Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
- Epidermal growth factor receptor expression and mutational Analysis in synovial sarcomas and malignant peripheral nerve sheath tumors.
- Safety and efficacy of arsenic trioxide for patients with advanced metastatic Melanoma.
- Role of histone deacetylases and their inhibitors in Cancer biology and treatment.
- Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced Melanoma and other solid tu...
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced Sarcoma.
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
American University of Beirut Faculty of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1982729422 | |
| NPPES Provider LastName | TAWBI | |
| NPPES Provider FirstName | HUSSEIN | |
| NPPES Provider ZIPCode | 152321309 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 280.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 7.86 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982729422 |
| Last Name Of The Provider | TAWBI |
| First Name Of The Provider | HUSSEIN |
| View All |
Similar Doctors
|
|
Dr. Barry C. Lembersky, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ronald G. Stoller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Friedland, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rachel C. Jankowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Swapna Goday, MD |
|
|
Dr. Aravind Sanjeevaiah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Bress, MD |